Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nabi-HB + Lamivudine in Liver Transplant
NCT01421212Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Nov 1999
- Primary completion
- Feb 2002
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hepatitis B immune globulin in hepatitis B (HBV), sponsored by Biotest AG. Primary endpoints: Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation and Number of participants who maintain a protective trough titer of anti hepatitis B antibodies beginning at 12 weeks post liver transplantation. Started Nov 1999; status: completed.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01421212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421212.